BioSig Tech. (BSGM) & Electrophysiology Sector - ViralClear - BioSig Tech. (BSGM) & Electrophysiology Sector - InvestorVillage
BioSig Tech. (BSGM) & Electrophysiology Sector (related stock BSGM)
  • TECH UPDATE: Please accept our apologies for the delay in getting our "board visit & message view" counts to normalize. As you may have noticed, starting yesterday the "board stats" for individual message boards started to display clearly erroneous "member" and "guest" visit counts. Needless to say, we don't like having unreliable traffic stats on the site any more than you do. Please understand this was not by design or intention. It's a glitch that resulted from an apparent incompatibility with the legacy code and the recent deployment of new servers to tackle issues related to last month's outage. In order to give our web developer a chance to take a closer look at the glitch and come up with a viable solution, we have decided to leave the code up for now so she can have real-world data to work with (rather than just turn the counts off again). So it looks like we may have to live with these bad counts a little longer, but our expectation is to have this resolved by early next week, if not sooner. We appreciate your patience and understanding.  
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: BioSig Tech. (BSGM) & Electrophysiology Sector   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1809 of 1871  at  9/24/2020 9:12:47 AM  by

amega21


ViralClear

I took a few days to review the transcript again just to try and ascertain the good and the bad of this call.

First , I do believe the stock most likely was going to go down no matter what was said on this call because the study is still BLINDED. There is only so much information that can be provided/discussed to make a call like this worthwhile, especially to retail investors. More negative questions arise then positive ones because you canít pinpoint and discuss specific milestones that were accomplished. The pressure to try update shareholders without specific detailed trial information in my opinion was a mistake. I personally believe the call should not have happened. Short term we obviously are paying the price and this became a feeding ground for shorts and margin investors. Not a good scenario. Long term this call becomes insignificant. The good is that even though nothing specific was discussed, we now know the trial was safe and effective. Showing an improvement in Group 3, most sick, is outstanding news. We need to see what that data is, but the fact the FDA expanded the trial tells me MMPD worked and it was safe. Most of us were definitely hoping for an immediate home run. Honestly the odds were against that happening unless a partner or grants occur (which I think is still in play)
From a call perspective, I was disappointed with the beginning the middle and the end of this presentation. After the Pure EP presentation, which I thought was organized and presented well, this presentation fell of the rails. Not one speaker sounded prepared and each spoke off the cuff. Sorry BioSig. My experience tells me its NOW time for BSGM to separate ViralClear from BioSig. We need to hire a CEO with a specific Pharma background, and experience with FDA drug approval connections. Someone that can handle being on the front lines with the ability to intelligently present ViralClear. Someone that can go on CNBC or other media that has credibility in the market so we can get a little respect. Let BioSig be BioSig and let ViralClear be ViralClear.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 10     Views: 680
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.
Loading...